Search results

The Covid-19 pandemic has affected men and women differently, exacerbating existing gender inequalities across a range of areas including health, education, and livelihoods. Globally, the levels of gender-based violence have increased. Consensus exists in policy circles that emergency response and recovery plans should consider both the immediate and longer-term gender impact of Covid-19, and without effective measures, the progress made to date on gender equality will not be sustainable. But has this crisis led to a moment when gender power hierarchies in our economies, politics, and society can be renegotiated? In this article, we explore: what does building back better look like if gender equality was at its core? What kinds of feminist dilemmas arise with respect to how we frame women's voice and agency as we advocate for transformative systemic change? We start with a vision for building back better with a gender lens; and move on to discuss the gender-specific impacts of Covid-19 that exacerbate the vulnerabilities of women and girls. In connection with the latter, we discuss the feminist dilemmas that arise with respect to discourse on women's agency, representation, participation, and the key issues that we need to consider for transforming systemic gender power hierarchies.

The Covid-19 pandemic has affected men and women differently, exacerbating existing gender inequalities across a range of areas including health, education, and livelihoods. Globally, the levels of gender-based violence have increased. Consensus exists in policy circles that emergency response and recovery plans should consider both the immediate and longer-term gender impact of Covid-19, and without effective measures, the progress made to date on gender equality will not be sustainable. But has this crisis led to a moment when gender power hierarchies in our economies, politics, and society can be renegotiated? In this article, we explore: what does building back better look like if gender equality was at its core? What kinds of feminist dilemmas arise with respect to how we frame women's voice and agency as we advocate for transformative systemic change? We start with a vision for building back better with a gender lens; and move on to discuss the gender-specific impacts of Covid-19 that exacerbate the vulnerabilities of women and girls. In connection with the latter, we discuss the feminist dilemmas that arise with respect to discourse on women's agency, representation, participation, and the key issues that we need to consider for transforming systemic gender power hierarchies. ; Irish Aid

IntroductionConcomitant use of combination antiretroviral regimen (cART) and cancer chemotherapy is difficult due to complex interactions and increased toxicity. Raltegravir could be an adequate option through its favourable drug‐drug interaction profile.MethodsProspective longitudinal study of HIV patients with cancer, AIDS related or not, undergoing chemotherapy. Patients without resistance or previous failure were switched or initiated raltegravir plus two nucleoside analogues. Plasma trough levels of raltegravir were measured.ResultsOverall, 28 patients receiving a raltegravir‐based regimen (4 naive) with tenofovir‐emtricitabine (18 cases) or abacavir‐lamivudine (10 cases) were included. Mean age was 46.2 years (IQR, 39–52.7), and 79% were male. Median time of HIV was 201.7 months, CD4+ nadir was 268 cells/mm3, and 75% had previous AIDS. At the diagnosis of neoplasia, 17 were on protease inhibitors and 4 with efavirenz. Ten patients had a non‐HIV‐related cancer (three breast, two pancreatic, one Ewing sarcoma, one myeloblastic leukemia, one melanoma, one parotid adenocarcinoma, one lung), and 18 had an HIV‐related cancer (nine non‐Hodgkin lymphoma, seven Hodgkin disease, two anal). Overall, 43% of patients received more than one line of chemotherapy, including antimetabolites in 12 patients (5‐FU, capecitabine, methotrexate, gemcitabine), alkylating agents in 12 cases (ciclophosphamide, iphosphamide), vinca alkaloids in 20 patients (vincristine, vinblastine, vindesine), antitumor antibiotics in 16 cases (adriamycin), cisplatin o carboplatin in six and monoclonal antibodies in six patients (rituximab, trastuzumab, cetuximab). Six patients modified the doses of antineoplastic agents due to toxicity (four neutropenia), not related to raltegravir. During a median follow up of 12.7 patients‐year in concomitant therapy, there was only 1 case of virological failure and no patient discontinued raltegravir. Plasma concentrations of raltegravir in eight patients showed a median concentration of 143 ng/mL (79–455). Four patients (14%) died during the study, not related to AIDS progression. Raltegravir was continued after chemotherapy in all the cases.ConclusionsA raltegravir‐based therapy is safe and effective in HIV patients undergoing antineoplastic chemotherapy, regardless of the type of tumour, and type and duration of chemotherapy. Pharmacokinetic data show adequate raltegravir levels.

What does research on informal sector workers and the state entail in the time of Covid-19? The pandemic has limited possibilities for in-person interactions and required adaptations in research approaches. These challenges are exacerbated when the subjects of the research are informal sector workers with limited access to technology and undefined spaces of work. In this article, we argue that the Covid-19 pandemic has magnified distances: between researchers located globally; between researchers and respondents; and between the state and people within informal employment. However, these distances also create new ways of working and opportunities for doing research. We discuss the challenges faced in the field, document the adaptations introduced to ensure robust research in difficult settings, and set out the limitations that remain. We also examine the ethical dimension of confronting dangerous misinformation related to the pandemic while conducting interviews, and the questions it raises about the distance between research and prescriptive advocacy in academia.